NEW YORK, March 12 – French biotechnology firm Abivax has firmly rejected reports from a French publication claiming the company had provided British pharmaceutical giant AstraZeneca with exclusive access to sensitive company data for a possible acquisition.
The reports from “La Lettre,” a French media outlet, alleged that Abivax had given AstraZeneca special access to confidential company information through March 23, potentially paving the way for AstraZeneca to make a formal buyout proposal.
However, an Abivax representative strongly pushed back against these claims on Tuesday.
“We deny the information, these are unfounded rumors,” the company spokesperson stated.
The denial comes as speculation swirls around potential consolidation in the biotechnology sector, though Abivax maintains no such discussions are taking place with the British pharmaceutical company.
